SAS, Thread launch proprietary offering for biopharma companies
John Reites of Thread
SAS and Thread have announced the launch of a proprietary offering that enables emerging biopharma companies to modernise their clinical research in a cost-effective way. AI and analytics provider SAS and Thread, a provider in decentralised research, have partnered on a new solution that supports biotech companies with data preparation, evaluation, and submission.
The newly launched offering combines SAS’ cloud-native analytics with Thread’s decentralised clinical trial (DCT) and electronic clinical outcome assessment (eCOA) platform to enable biopharma companies to better control and oversee their clinical study data. The regulatory compliance-enabled solution features a consolidated analytics environment that pulls data from multiple sources, including participant- and clinician-reported data provided by Thread. For larger pharmaceutical organisations, Thread’s data also can be surfaced within customer-specific SAS analytical environments.
“To meet the evolving needs of clinical trial participants in the age of digital health, research organisations are transforming the way they discover, develop, manufacture, and commercialise new therapies,” says John Reites, co-founder and CEO, Thread. “We are excited to partner with SAS to provide this unique solution to biopharma customers who want to collect data via next-generation research designs.”
The new partnership starts with the integration of SAS’ statistical computing environment (SCE) solution, built on SAS Viya, SAS’ cloud-native and analytics platform, with Thread’s technology platform providing data access, analysis, and visualisation for shared customers. It will allow the two organisations to build on their initial collaboration into DCT-specific analytics by combining the data elements captured by Thread with SAS AI, machine learning, and visualisation.
“With SAS and Thread, biotech companies can modernise clinical research and deliver new therapies to market faster to improve health. And more of their people will benefit from advanced analytics,” says Jason Mann, vice president of Internet of Things (IoT) at SAS.
Comment on this article below or via Twitter @IoTGN